Improving pregnancy outcomes in older women undergoing IVF
A Single-center Randomized Controlled Trial on Mevalproic Acid Improving Oocyte Quality and Embryo Development in Elderly Infertile Patients
This study is testing if a medication called Mevalproic acid can help older women who are having trouble getting pregnant through IVF have better pregnancy outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 148 (estimated) |
| Ages | 38 Years to 42 Years |
| Sex | Female |
| Sponsor | Nanjing University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT05788822 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of Mevalproic acid (MVA) in enhancing pregnancy outcomes for elderly women facing infertility who are undergoing in vitro fertilization (IVF). Participants will have their oocytes randomly divided into two groups: one treated with MVA and the other receiving standard care without MVA. The study will assess whether MVA can improve the haploid rate of embryos, which is crucial for successful fertilization and pregnancy. The trial follows a randomized controlled design to ensure unbiased results.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged between 38 and 42 years who have undergone no more than two IVF cycles.
Not a fit: Patients who are egg donors, have chromosomal abnormalities, or suffer from certain uterine diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the chances of pregnancy for older women undergoing IVF.
How similar studies have performed: While the use of MVA in this context is novel, similar studies have shown promising results in improving reproductive outcomes with various interventions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 38 years ≤ age ≤ 42 years; 2. Number of IVF/ICSI cycles ≤ 2 Exclusion Criteria: 1. Egg donor cycle 2. Chromosome abnormality; 3. Adenomyosis, hysteromyoma, thin endometrium, endometriosis and other uterine diseases; 4. Patients with repeated implantation failure
Where this trial is running
Nanjing, Jiangsu
- Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Haixiang Sun, MD
- Email: haixiang_sun@nju.edu.cn
- Phone: 025-83106666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.